Coya Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Miscellaneous
  • ISIN: US22407B1089
USD
4.76
-0.1 (-2.06%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Research Solutions, Inc.
Science 37 Holdings, Inc.
1847 Holdings LLC
Gaia, Inc.
Coya Therapeutics, Inc.
Katapult Holdings, Inc.
Inotiv, Inc.
Harte-Hanks, Inc.
Celularity, Inc.
Network-1 Technologies, Inc
Benson Hill, Inc.

Why is Coya Therapeutics, Inc. ?

1
Flat results in Jun 25
  • NET SALES(HY) At USD 0.42 MM has Grown at -88.13%
  • PRE-TAX PROFIT(Q) At USD -6.09 MM has Fallen at -110.78%
  • NET PROFIT(Q) At USD -6.09 MM has Fallen at -110.78%
2
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 1.51%, its profits have fallen by -74.7%
3
Underperformed the market in the last 1 year
  • The stock has generated a return of 1.51% in the last 1 year, much lower than market (S&P 500) returns of 15.98%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Coya Therapeutics, Inc. should be less than 10%
  2. Overall Portfolio exposure to Miscellaneous should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Miscellaneous)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Coya Therapeutics, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Coya Therapeutics, Inc.
-23.47%
-0.37
65.69%
S&P 500
15.4%
0.81
19.85%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
5.55%
EBIT Growth (5y)
-284.91%
EBIT to Interest (avg)
-7.54
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.06
Sales to Capital Employed (avg)
0.13
Tax Ratio
4.03%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
35.93%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.94
EV to EBIT
-3.23
EV to EBITDA
-3.23
EV to Capital Employed
-29.02
EV to Sales
17.02
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-51.35%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company
NET PROFIT(HY)

Higher at USD -13.4 MM

DEBT-EQUITY RATIO (HY)

Lowest at -105.11 %

-26What is not working for the Company
NET SALES(HY)

At USD 0.42 MM has Grown at -88.13%

PRE-TAX PROFIT(Q)

At USD -6.09 MM has Fallen at -110.78%

NET PROFIT(Q)

At USD -6.09 MM has Fallen at -110.78%

OPERATING CASH FLOW(Y)

Lowest at USD -16.47 MM

ROCE(HY)

Lowest at -63.99%

Here's what is working for Coya Therapeutics, Inc.

Debt-Equity Ratio
Lowest at -105.11 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for Coya Therapeutics, Inc.

Net Sales
At USD 0.42 MM has Grown at -88.13%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very negative

Net Sales (USD MM)

Pre-Tax Profit
At USD -6.09 MM has Fallen at -110.78%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit
At USD -6.09 MM has Fallen at -110.78%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (USD MM)

Operating Cash Flow
Lowest at USD -16.47 MM
in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)